Literature DB >> 24718468

[Prognostic value of the lethal triad among patients with multiple trauma].

María González Balverde, Ernesto J Ramírez Lizardo, Ernesto G Cardona Muñoz, Sylvia E Totsuka Sutto, Leonel García Benavides.   

Abstract

BACKGROUND: Patients who have suffered multiple traumatic injuries, have a serious risk for death. Hypothermia, acidosis and coagulopathy are three complications in these patients, whose presence is known as lethal triad and indicates bad prognosis. AIM: To determine if the lethal triad in multiple trauma patients is associated with higher mortality and Injury Score Severity (ISS).
MATERIAL AND METHODS: One hundred multiple trauma patients aged 26 to 56 years (90 males), admitted to an emergency room, were studied. Body temperature, prothrombin time, partial thromboplastin time, platelet count and blood gases were determined on admission.
RESULTS: Twenty six patients had the lethal triad and 15% died in the emergency room within the first 6 hours. No death was recorded among the 74 patients without the lethal triad. The mean ISS among patients with and without the lethal triad was 31.7 and 25.6, respectively (p < 0.05).
CONCLUSIONS: The presence of the lethal triad among patients with multiple trauma is associated with a higher mortality and ISS.

Entities:  

Mesh:

Year:  2013        PMID: 24718468     DOI: 10.4067/S0034-98872013001100008

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  2 in total

1.  Comparison of base excess, lactate and pH predicting 72-h mortality of multiple trauma.

Authors:  Junfang Qi; Long Bao; Peng Yang; Du Chen
Journal:  BMC Emerg Med       Date:  2021-07-07

2.  Clinical and biochemical factors associated with survival in equids attacked by dogs: 28 cases (2008-2016).

Authors:  C Langdon Fielding; Jennifer R Mayer; Julie E Dechant; Kira L Epstein; K Gary Magdesian
Journal:  J Vet Intern Med       Date:  2020-12-04       Impact factor: 3.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.